ZHANG Xinyu,LU Yunqi,SHEN Hanbing,et al.Clinical observation of acupuncture combined with conventional therapy for treatment of antipsychotic drug⁃induced metabolic syndrome[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(1):58-62.
ZHANG Xinyu,LU Yunqi,SHEN Hanbing,et al.Clinical observation of acupuncture combined with conventional therapy for treatment of antipsychotic drug⁃induced metabolic syndrome[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(1):58-62. DOI: 10.16305/j.1007-1334.2022.2104042.
Clinical observation of acupuncture combined with conventional therapy for treatment of antipsychotic drug⁃induced metabolic syndrome
Objective,2,To observe the clinical efficacy of acupuncture combined with conventional therapy for antipsychotic drug-induced metabolic syndrome.,Methods,2,Ninety-three schizophrenia patients complicated with metabolic syndrome of qi deficiency and phlegm stagnancy syndrome were randomly divided into a control group (,n,=46) and a treatment group (,n,=47). The control group was administered with conventional medication and lifestyle interventions, while the treatment group was additionally administered with acupuncture treatment besides the treatment measures of the control group. The course of treatment for both groups was 3 months, and the patients were followed up constantly for 6 months after the end of treatment. Our research group also observed and compared the changes of the World Health Organization Quality of Life Assessment-BREF (WHO-QOL-BREF) score, the Global Assessment of Functioning (GAF) score, the Clinical Global Impressions scale (severity of illness and global improvement measures) (CGI-SI) score, Treatment Emergent Symptom Scale (TESS) score, waist circumference, hip circumference, body mass index, blood pressure and other general conditions, as well as the changes of total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), fasting blood glucose (FPG), glycated hemoglobin (HbA1c) and other lab text indexes.,Results,2,①During the trial, there was one drop-out case in each group, and 91 cases finally completed the trial, including 46 cases in the treatment group and 45 cases in the control group. ②During the trial, there were no significant changes in WHO-QOL-BREF, GAF, CGI-SI and TESS scores, body mass index, waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, and related laboratory indexes in the control group (,P>,0.05). ③Patients in the treatment group showed higher GAF scores and WHO-QOL-BREF scores in physical domain and psychological domain (,P,<,0.05), lower CGI-SI and TESS scores (,P,<,0.05), and improved lipid-related laboratory indexes (,P,<,0.05) after 3 months. However, the above indexes rebounded to different degrees after 6 months, which were still better than those in the control group (,P,<,0.05).,Conclusion,2,Compared with conventional medication and life interventions, the additional treatment of acupuncture for antipsychotic drug-induced metabolic syndrome has more satisfactory efficacy and can assist the treatment of mental diseases with long-lasting effects.
ALBERTI K G, ECKEL R H, GRUNDY S M, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation, 2009, 120(16): 1640-1645.
MOTTILLO S, FILION K B, GENEST J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis[J]. J Am Coll Cardiol, 2010, 56(14): 1113-1132.
ZHANG J P, GALLEGO J A, ROBINSON D G, et al. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis[J]. Int J Neuropsychopharmacol, 2013, 16(6): 1205-1218.
ROJO L E, GASPAR P A, SILVA H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology[J/OL]. Pharmacol Res, 2015, 101:74-85[2021-03-30]. https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(15)00155-3https://linkinghub.elsevier.com/retrieve/pii/S1043-6618(15)00155-3.
BRITVIC D, MARIC N P, DOKNIC M, et al. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review[J]. Psychiatr Danub, 2013, 25(4): 410-415.
STEINLECHNER S, WENZEL L, KASTEN M, et al. Evaluation of psychiatric disorders on the basis of a SCID screening[J]. Fortschr Neurol Psychiatr, 2015, 83(9): 499-505.
LI C H, SHI L, ZHAN G L, et al. A twenty-four-week, open-labelstudy on ziprasidone’s efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder[J]. Eur Rev Med Pharmacol Sci, 2013, 17(16): 2136-2140.